SUPN - Supernus Pharmaceuticals, Inc.
| Previous Close | 24.69 |
| Open | 24.78 |
| Bid | 24.25 x 800 |
| Ask | 24.38 x 1100 |
| Day's Range | 24.30 - 24.99 |
| 52 Week Range | 19.35 - 43.05 |
| Volume | 398,061 |
| Avg. Volume | 706,901 |
| Market Cap | 1.279B |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | 12.43 |
| EPS (TTM) | 1.96 |
| Earnings Date | Feb 23, 2020 - Feb 27, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
- Benzinga
The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 21) Abbott Laboratories (NYSE: ABT ) Apellis Pharmaceuticals ...
- GlobeNewswire
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has found the New Drug Application (NDA) for SPN-812 for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) acceptable for review. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, SPN-810 for the treatment of impulsive aggression, and SPN-604 for the treatment of bipolar disorder.
- Zacks
Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?
Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.
- Simply Wall St.
Here's Why We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Is Well Worth Watching
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
- GlobeNewswire
Supernus to Present at the 2020 J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 08, 2020 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Simply Wall St.
Here's How P/E Ratios Can Help Us Understand Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...
- Insider Monkey
Do Hedge Funds Love Supernus Pharmaceuticals Inc (SUPN)?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before last year's Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the […]
- Benzinga
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
- GlobeNewswire
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, is providing an update on the results from the first Phase III study (P301) of SPN-810, a novel treatment of Impulsive Aggression (IA) in patients with ADHD. In early November 2019, the Company reported topline results from the Phase III P301 trial in patients 6 to 11 years. In stage 1 (interim analysis stage), the median percent reduction was 60.0%, which was statistically significant (p=0.029) compared to placebo.
- Simply Wall St.
Investors Who Bought Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Five Years Ago Are Now Up 148%
It hasn't been the best quarter for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders, since the share price...
- American City Business Journals
Supernus Pharmaceuticals seeks FDA approval for ADHD drug
The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD symptoms.
- GlobeNewswire
Supernus to Present at Two November Healthcare Conferences
ROCKVILLE, Md., Nov. 12, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- GlobeNewswire
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SPN-812 for the treatment of patients with attention deficit hyperactivity disorder (ADHD). SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD. It is a non-controlled substance that is easy to use and that has shown in clinical studies a reduction in ADHD symptoms observed as early as week one and continued until the end of the studies.
- Thomson Reuters StreetEvents
Edited Transcript of SUPN earnings conference call or presentation 6-Nov-19 2:00pm GMT
Q3 2019 Supernus Pharmaceuticals Inc Earnings Call
- TheStreet.com
How to Profit From Market Overreactions
A look at Supernus Pharmaceuticals and TPI Composites provides a tutorial on reaping rewards from stocks the market suddenly hates.
- Benzinga
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
- Benzinga
The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
- Zacks
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
Total revenue of $102.1 million, compared to $103.0 million in third quarter 2018Net product sales of $100.0 million, compared to $100.2 million in third quarter 2018Operating.
- Zacks
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Were Hedge Funds Right About Dumping Supernus Pharmaceuticals Inc (SUPN)?
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
- GlobeNewswire
Supernus to Host Third Quarter 2019 Earnings Conference Call
ROCKVILLE, Md., Oct. 24, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Simply Wall St.
Estimating The Fair Value Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Does the October share price for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reflect what it's really worth? Today...
- Simply Wall St.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
